MyMD Pharmaceuticals Inc (MYMD)

[BioFan1]

JOHN MAULDIN ON BOARD!

The legendary economist John Mauldin revealed in a recent article that he is a believer in, and a shareholder of, MYMD. Mauldin is the founder of Mauldin Economics, a financial expert, and NY Times best-selling author. In a March 25 Thoughts from the Frontline article, he summarized the MYMD story and disclosed his ownership interest:

Let’s start with some very new research from a company called MyMD Pharmaceuticals. (Full disclosure: I am an investor but have no other financial relationship with the company.) This is clearly in the fountain of middle age category.

Their drug, MYMD-1 is a TNF-a inhibitor, like Humira and the other monoclonal antibodies (mAbs) that make up a $25 billion market treating multiple serious diseases. Unlike mAbs, which are grown from human or animal cells, MYMD-1 is a synthesized version of a naturally occurring molecule found in plants. It's also safer than the mAbs that come with a black box warning indicating serious risk. Moreover, it doesn’t have to be injected. It is a simple pill and, based on a phase 1 human trial, has virtually no side effects.

The most important thing about TNF-a is that it is a major driver of aging itself.

Link to full article:

https://www.mauldineconomics.com/frontlinethoughts/things-are-getting-better#healthcare